The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Cellular prion protein mediates impairment of synaptic plasticity by amyloid-β oligomers
Open accessAbstract
A pathological hallmark of Alzheimer's disease is an accumulation of insoluble plaque containing the amyloid-beta peptide of 40-42 amino acid residues. Prefibrillar, soluble oligomers of amyloid-beta have been recognized to be early and key intermediates in Alzheimer's-disease-related synaptic dysfunction. At nanomolar concentrations, soluble amyloid-beta oligomers block hippocampal long-term potentiation, cause dendritic spine retraction from pyramidal cells and impair rodent spatial memory. Soluble amyloid-beta oligomers have been prepared from chemical syntheses, transfected cell culture supernatants, transgenic mouse brain and human Alzheimer's disease brain. Together, these data imply a high-affinity cell-surface receptor for soluble amyloid-beta oligomers on neurons-one that is central to the pathophysiological process in Alzheimer's disease. Here we identify the cellular prion protein (PrP(C)) as an amyloid-beta-oligomer receptor by expression cloning. Amyloid-beta oligomers bind with nanomolar affinity to PrP(C), but the interaction does not require the infectious PrP(Sc) conformation. Synaptic responsiveness in hippocampal slices from young adult PrP null mice is normal, but the amyloid-beta oligomer blockade of long-term potentiation is absent. Anti-PrP antibodies prevent amyloid-beta-oligomer binding to PrP(C) and rescue synaptic plasticity in hippocampal slices from oligomeric amyloid-beta. Thus, PrP(C) is a mediator of amyloid-beta-oligomer-induced synaptic dysfunction, and PrP(C)-specific pharmaceuticals may have therapeutic potential for Alzheimer's disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Among the Aβ binding candidates, cellular prion protein (PrPc) represents the most studied, either alone or through a complex with mGluR5 [37, 62, 72, 79].”
From Transmembrane protein 97 is a potential synaptic amyloid beta receptor in human Alzheimer’s disease (2024) · cites this paper as [37]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The most studied binding partner is the PrPc, which through a cascade involving a complex with mGluR5 may lead to toxicity independently or via tau [37, 62, 72, 79].”
From Transmembrane protein 97 is a potential synaptic amyloid beta receptor in human Alzheimer’s disease (2024) · cites this paper as [37]
Experimental — accuracy not yet measuredIn the citing paper
“Aβ binds to α7 nicotinic acetylcholine receptors (α7 nAChRs) and to metabotropic glutamate receptors, in particular mGluR5 [31–33].”
From ApoE, ApoE Receptors, and the Synapse in Alzheimer's Disease (2017) · cites this paper as [33]
In the citing paper
“A genome-wide association study (GWAS) identified PrPC as a potential high-affinity receptor for oAβ [87].”
From Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer’s disease (2020) · cites this paper as [87]
In the citing paper
“Subsequent studies showed that oAβ, especially high-molecular weight oligomers [88], preferentially bind to PrPC within an N-terminal 95-111aa segment [87].”
From Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer’s disease (2020) · cites this paper as [87]
In the citing paper
“oligomer binding is significantly reduced in PrPC knock-out cells (Lauren et al., 2009).”
From The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer’s disease (2011) · cites this paper as Lauren et al., 2009
In the citing paper
“Aβ oligomers bind with nanomolar affinity to cellular prion protein (PrPC) and that anti-PrP antibodies reduce oligomer binding to neurons and rescue synaptic plasticity (Lauren et al., 2009).”
From The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer’s disease (2011) · cites this paper as Lauren et al., 2009
In the citing paper
“explaining the finding that knocking-down these proteins or adding antibodies against their extracellular domains blocks the accumulation of ADDL clusters (“hotspots”) at synapses (De Felice et al., 2007; Decker et al., 2010a; Lauren et al., 2009).”
From The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer’s disease (2011) · cites this paper as Lauren et al., 2009
In the citing paper
“PrPC binds synthetic Aβ oligomers with high affinity and plays a role in the oligomer-mediated inhibition of LTP (17).”
From Synthetic amyloid-β oligomers impair long-term memory independently of cellular prion protein (2010) · cites this paper as [17]
In the citing paper
“In an elegant study Lauren et al. (17) reported that PrPC mediates the Aβ oligomer-induced hippocampal synaptic plasticity impairment.”
From Synthetic amyloid-β oligomers impair long-term memory independently of cellular prion protein (2010) · cites this paper as [17]
In the citing paper
“The 22 °C-Aβ oligomers impaired recognition memory in both Prnp +/+ and Prnp 0/0 mice (Fig. 4C).”
From Synthetic amyloid-β oligomers impair long-term memory independently of cellular prion protein (2010) · cites this paper as [17]
In the citing paper
“When amyloid-β oligomers bind to PrPc, long-term potentiation and the formation of new memories are disrupted [129,130,131].”
From Sigma-2 Receptors—From Basic Biology to Therapeutic Target: A Focus on Age-Related Degenerative Diseases (2023) · cites this paper as [130]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED ARTICLE: A specific amyloid-β protein assembly in the brain impairs memory
Lesné, S., Koh, M. T., Kotilinek, L., Kayed, R., Glabe, C. G., Yang, A., Gallagher, M., & Ashe, K. H. (2006) · Nature · doi:10.1038/nature04533 · Cited by 2,769
RetractedThe Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
Prusiner, S. B. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.23.13363 · Cited by 5,373
Walsh, D. M., Klyubin, I., Fadeeva, J. V., Cullen, W. K., Anwyl, R., Wolfe, M. S., Rowan, M. J., & Selkoe, D. J. (2002) · Nature · doi:10.1038/416535a · Cited by 4,291
Shankar, G. M., Li, S., Mehta, T. H., Garcia-Munoz, A., Shepardson, N. E., Smith, I., Brett, F. M., Farrell, M. A., Rowan, M. J., Lemere, C. A., et al. (2008) · Nature Medicine · doi:10.1038/nm1782 · Cited by 3,685
Diffusible, nonfibrillar ligands derived from Aβ 1–42 are potent central nervous system neurotoxins
Lambert, M. P., Barlow, A. K., Chromy, B. A., Edwards, C., Freed, R., Liosatos, M., Morgan, T. E., Rozovsky, I., Trommer, B., Viola, K. L., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.11.6448 · Cited by 3,506
RAGE and amyloid-β peptide neurotoxicity in Alzheimer's disease
Yan, S. D., Chen, X., Fu, J., Chen, M., Zhu, H., Roher, A., Slattery, T., Zhao, L., Nagashima, M., Morser, J., et al. (1996) · Nature · doi:10.1038/382685a0 · Cited by 2,012
Natural oligomers of the amyloid-β protein specifically disrupt cognitive function
Cleary, J. P., Walsh, D. M., Hofmeister, J. J., Shankar, G. M., Kuskowski, M. A., Selkoe, D. J., & Ashe, K. H. (2004) · Nature Neuroscience · doi:10.1038/nn1372 · Cited by 1,722
Normal development and behaviour of mice lacking the neuronal cell-surface PrP protein
Büeler, H., Fischer, M., Lang, Y., Bluethmann, H., Lipp, H., DeArmond, S. J., Prusiner, S. B., Aguet, M., & Weissmann, C. (1992) · Nature · doi:10.1038/356577a0 · Cited by 1,676
Shankar, G. M., Bloodgood, B. L., Townsend, M., Walsh, D. M., Selkoe, D. J., & Sabatini, B. L. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.4970-06.2007 · Cited by 1,592
Flagged first, then by citations
Cited by
Sorted by citations
Items 501–600 of 1,002
ACU193: An Immunotherapeutic Poised to Test the Amyloid β Oligomer Hypothesis of Alzheimer’s Disease
Krafft, G. A., Jerecı̀ć, J., Siemers, E., & Cline, E. N. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.848215 · Cited by 54
Liu, L., Xia, N., Jiang, M., Huang, N., Guo, S., Li, S., & Zhang, S. (2015) · Journal of Electroanalytical Chemistry · doi:10.1016/j.jelechem.2015.06.017 · Cited by 52
Cellular Prion Protein as a Therapeutic Target in Alzheimer's Disease
Laurén, J. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-130950 · Cited by 55
Self-citationBrogi, S., Butini, S., Maramai, S., Colombo, R., Verga, L., Lanni, C., Lorenzi, E. D., Lamponi, S., Andreassi, M. G., Bartolini, M., et al. (2014) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.12290 · Cited by 51
Highly neurotoxic monomeric α-helical prion protein
Zhou, M., Ottenberg, G. K., Sferrazza, G. F., & Lasmézas, C. I. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1118090109 · Cited by 51
Influence of ADAM10 on prion protein processing and scrapie infectiosity in vivo
Endres, K., Mitteregger, G., Kojro, E., Kretzschmar, H. A., & Fahrenholz, F. (2009) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.07.015 · Cited by 51
Evidence of Rapid Coaggregation of Globular Proteins during Amyloid Formation
Dubey, K., Anand, B. G., Temgire, M., & Kar, K. (2014) · Biochemistry · doi:10.1021/bi501333q · Cited by 51
Soluble Conformers of Aβ and Tau Alter Selective Proteins Governing Axonal Transport
Sherman, M. A., LaCroix, M., Amar, F., Larson, M. E., Forster, C. L., Aguzzi, A., Bennett, D. A., Ramsden, M., & Lesné, S. (2016) · Journal of Neuroscience · doi:10.1523/jneurosci.1899-16.2016 · Cited by 51
Zhang, H., Zhang, L., Zhou, D., He, X., Wang, D., Pan, H., Zhang, X., Mei, Y., Qian, Q., Zheng, T., et al. (2017) · Neurobiology of Disease · doi:10.1016/j.nbd.2017.07.001 · Cited by 54
SORLA attenuates EphA4 signaling and amyloid β–induced neurodegeneration
Huang, T. Y., Zhao, Y., Jiang, L.-L., Li, X., Liu, Y., Sun, Y., Piña-Crespo, J. C., Zhu, B., Masliah, E., Willnow, T. E., et al. (2017) · Journal of Experimental Medicine · doi:10.1084/jem.20171413 · Cited by 50
Webber, E. K., Fivaz, M., Stutzmann, G. E., & Griffioen, G. (2023) · Alzheimer's & Dementia · doi:10.1002/alz.13065 · Cited by 50
Madhu, P., & Mukhopadhyay, S. (2021) · Journal of Cellular Biochemistry · doi:10.1002/jcb.30141 · Cited by 53
Mehrabian, M., Dylan, B., Wang, H., Xi, Z., Rogaeva, E. A., & Schmitt‐Ulms, G. (2015) · PLoS ONE · doi:10.1371/journal.pone.0133741 · Cited by 50
Sáez-Orellana, F., Godoy, P. A., Bastidas, C. Y., Silva-Grecchi, T., Guzmán, L., Aguayo, L. G., & Fuentealba, J. (2015) · Neuropharmacology · doi:10.1016/j.neuropharm.2015.04.005 · Cited by 50
Mechanisms of prion-induced neurodegeneration
Saá, P., Harris, D. A., & Červen̆áková, L. (2016) · Expert Reviews in Molecular Medicine · doi:10.1017/erm.2016.8 · Cited by 50
Inhibition of group-I metabotropic glutamate receptors protects against prion toxicity
Goniotaki, D., Lakkaraju, A. K., Shrivastava, A. N., Bakirci, P., Sorce, S., Senatore, A., Marpakwar, R., Hornemann, S., Gasparini, F., Triller, A., et al. (2017) · PLoS Pathogens · doi:10.1371/journal.ppat.1006733 · Cited by 52
Brain Inflammation Connects Cognitive and Non-Cognitive Symptoms in Alzheimer’s Disease
Sellés, M. C., Oliveira, M. M., & Ferreira, S. T. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-179925 · Cited by 51
Muskelin Coordinates PrPC Lysosome versus Exosome Targeting and Impacts Prion Disease Progression
Heisler, F. F., Pechmann, Y., Wieser, I., Altmeppen, H. C., Veenendaal, L., Muhia, M., Schweizer, M., Glatzel, M., Krasemann, S., & Kneussel, M. (2018) · Neuron · doi:10.1016/j.neuron.2018.08.010 · Cited by 50
VEGF counteracts amyloid-β-induced synaptic dysfunction
Martin, L., Bouvet, P., Chounlamountri, N., Watrin, C., Besançon, R., Pinatel, D., Meyronet, D., Honnorat, J., Buisson, A., Salin, P. A., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109121 · Cited by 52
Cellular Prion Protein Regulates Its Own α-Cleavage through ADAM8 in Skeletal Muscle
Liang, J., Wang, W., Sorensen, D., Medina, S. J., Ilchenko, S. A., Kiselar, J., Surewicz, W. K., Booth, S. A., & Kong, Q. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.360891 · Cited by 49
Allosteric function and dysfunction of the prion protein
Linden, R., Cordeiro, Y., & Lima, L. M. T. R. (2011) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-011-0847-7 · Cited by 49
The Cellular Prion Protein: A Player in Immunological Quiescence
Bakkebø, M. K., Mouillet‐Richard, S., Espenes, A., Goldmann, W., Tatzelt, J., & Tranulis, M. A. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00450 · Cited by 49
Ganzinger, K. A., Narayan, P. S., Qamar, S., Weimann, L., Ranasinghe, R. T., Aguzzi, A., Dobson, C. M., McColl, J. T., George‐Hyslop, P. S., & Klenerman, D. (2014) · ChemBioChem · doi:10.1002/cbic.201402377 · Cited by 50
Stoeck, K., Schmitz, M., Ebert, E., Schmidt, C., & Zerr, I. (2014) · Journal of Neuroinflammation · doi:10.1186/s12974-014-0170-y · Cited by 49
Scott-McKean, J. J., Surewicz, K. A., Choi, J.-K., Ruffin, V. A., Salameh, A., Nieznański, K., Costa, A. C. S., & Surewicz, W. K. (2016) · Neurobiology of Disease · doi:10.1016/j.nbd.2016.03.001 · Cited by 49
How the shapes of seeds can influence pathology
Melki, R. (2017) · Neurobiology of Disease · doi:10.1016/j.nbd.2017.03.011 · Cited by 50
Qin, J., Jo, D., Cho, M., & Lee, Y. (2018) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2018.04.061 · Cited by 49
Discovery of a Class of Diketopiperazines as Antiprion Compounds
Bolognesi, M. L., Tran, H. N. A., Staderini, M., Monaco, A., López‐Cobeñas, A., Bongarzone, S., Biarnés, X., López‐Alvarado, P., Cabezas, N., Caramelli, M., et al. (2010) · ChemMedChem · doi:10.1002/cmdc.201000133 · Cited by 49
Picosecond dissociation of amyloid fibrils with infrared laser: A nonequilibrium simulation study
Man, V. H., Derreumaux, P., Li, M. S., Roland, C., Sagui, C., & Nguyen, P. H. (2015) · The Journal of Chemical Physics · doi:10.1063/1.4933207 · Cited by 48
A Mutant Prion Protein Sensitizes Neurons to Glutamate-Induced Excitotoxicity
Biasini, E., Unterberger, U., Solomon, I. H., Massignan, T., Senatore, A., Bian, H.-J., Voigtländer, T., Bowman, F. P., Bonetto, V., Chiesa, R., et al. (2013) · Journal of Neuroscience · doi:10.1523/jneurosci.3406-12.2013 · Cited by 48
The role of synaptic activity in the regulation of amyloid beta levels in Alzheimer's disease
Cheng, X., Wu, J., Geng, M., & Xiong, J. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.11.021 · Cited by 51
Wang, H.-Y., Lee, K.-C., Pei, Z., Khan, A., Bakshi, K. P., & Burns, L. H. (2017) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2017.03.016 · Cited by 48
RetractedVEGF receptor‐1 modulates amyloid β 1–42 oligomer‐induced senescence in brain endothelial cells
Angom, R. S., Wang, Y., Wang, E., Pal, K., Bhattacharya, S., Watzlawik, J. O., Rosenberry, T. L., Das, P., & Mukhopadhyay, D. (2018) · The FASEB Journal · doi:10.1096/fj.201802003r · Cited by 49
HLA in Alzheimer’s Disease: Genetic Association and Possible Pathogenic Roles
Wang, Z., Wan, Q., & Xing, A. (2020) · NeuroMolecular Medicine · doi:10.1007/s12017-020-08612-4 · Cited by 48
Role of MicroRNAs, Aptamers in Neuroinflammation and Neurodegenerative Disorders
Khan, I., Kumari, P., Fernandes, V., Khatri, D. K., & Singh, S. B. (2021) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-021-01093-4 · Cited by 49
Extracellular Alpha-Synuclein: Mechanisms for Glial Cell Internalization and Activation
Chavarría, C., Ivagnes, R., & Souza, J. M. (2022) · Biomolecules · doi:10.3390/biom12050655 · Cited by 47
Real-time observation of model membrane dynamics induced by Alzheimer's amyloid beta
Morita, M., Vestergaard, M. C. M., Hamada, T., & Takagi, M. (2009) · Biophysical Chemistry · doi:10.1016/j.bpc.2009.12.004 · Cited by 48
Rezaei‐Ghaleh, N., Andreetto, E., Yan, L., Kapurniotu, A., & Zweckstetter, M. (2011) · PLoS ONE · doi:10.1371/journal.pone.0020289 · Cited by 47
PrP mRNA and protein expression in brain and PrPcin CSF in Creutzfeldt-Jakob disease MM1 and VV2
Llorens, F., Ansoleaga, B., Garcia‐Esparcia, P., Zafar, S., Grau‐Rivera, O., López‐González, I., Blanco, R., Carmona, M., Yagüe, J., Nos, C., et al. (2013) · Prion · doi:10.4161/pri.26416 · Cited by 49
Identification of a gene regulatory network associated with prion replication
Marbiah, M. M., Harvey, A., West, B. T., Louzolo, A., Banerjee, P., Alden, J., Grigoriadis, A. E., Hummerich, H., Kan, H.-M., Cai, Y., et al. (2014) · The EMBO Journal · doi:10.15252/embj.201387150 · Cited by 47
QIAD assay for quantitating a compound’s efficacy in elimination of toxic Aβ oligomers
Brener, O., Dunkelmann, T., Gremer, L., van Groen, T., Mirecka, E. A., Kadish, I., Willuweit, A., Kutzsche, J., Jürgens, D., Rudolph, S., et al. (2015) · Scientific Reports · doi:10.1038/srep13222 · Cited by 50
Characterization of prion protein function by focal neurite stimulation
Amin, L., Nguyen, X. T. A., Rolle, I. G., D’Este, E., Giachin, G., Tran, T. H., Šerbec, V. Č., Cojoc, D., & Legname, G. (2016) · Journal of Cell Science · doi:10.1242/jcs.183137 · Cited by 47
Kam, T., Park, H., Gwon, Y., Song, S., Kim, S.-H., Moon, S. W., Jo, D., & Jung, Y. (2016) · eLife · doi:10.7554/elife.18691 · Cited by 47
Disease-modifying benefit of Fyn blockade persists after washout in mouse Alzheimer's model
Smith, L. M., Zhu, R., & Strittmatter, S. M. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.11.042 · Cited by 49
Self-citationPharmacological Agents Targeting the Cellular Prion Protein
Barreca, M. L., Iraci, N., Biggi, S., Cecchetti, V., & Biasini, E. (2018) · Pathogens · doi:10.3390/pathogens7010027 · Cited by 49
Protein Co-Aggregation Related to Amyloids: Methods of Investigation, Diversity, and Classification
Bondarev, S. A., Antonets, K. S., Kajava, A. V., Nizhnikov, A. A., & Zhouravleva, G. A. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19082292 · Cited by 49
Zhang, H., Wu, S., & Xing, D. (2011) · APOPTOSIS · doi:10.1007/s10495-011-0608-y · Cited by 47
Jovanovic, K., Chetty, C. J., Khumalo, T., Dias, B. D. C., Ferreira, E., Malindisa, S. T., Caveney, R. J., Letsolo, B. T., & Weiss, S. F. T. (2015) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2015.1014802 · Cited by 48
The cellular prion protein (PrPC) as neuronal receptor for α-synuclein
Urrea, L., Ferrer, I., Gavı́n, R., & del Rı́o, J. A. (2017) · Prion · doi:10.1080/19336896.2017.1334748 · Cited by 49
Bioactive human Alzheimer brain soluble Aβ: pathophysiology and therapeutic opportunities
Li, S., & Stern, A. M. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01589-5 · Cited by 47
Eph receptors: New players in Alzheimer's disease pathogenesis
Cissé, M., & Checler, F. (2014) · Neurobiology of Disease · doi:10.1016/j.nbd.2014.08.028 · Cited by 50
Bignante, E. A., Heredia, F., Morfini, G. A., & Lorenzo, A. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.04.021 · Cited by 50
A domain level interaction network of amyloid precursor protein and Aβ of Alzheimer's disease
Perreau, V. M., Orchard, S. E., Adlard, P. A., Bellingham, S. A., Cappai, R., Ciccotosto, G. D., Cowie, T., Crouch, P. J., Duce, J. A., Evin, G. M., et al. (2010) · PROTEOMICS - CLINICAL APPLICATIONS · doi:10.1002/pmic.200900773 · Cited by 49
Xing, Y., Feng, X., Zhang, L., Hou, J., Han, G., & Chen, Z. (2017) · International Journal of Nanomedicine · doi:10.2147/ijn.s132776 · Cited by 46
Zhao, Y., Sivaji, S., Chiang, M. C., Ali, H., Zukowski, M., Ali, S. T., Kennedy, B., Sklyar, A., Cheng, A., Guo, Z., et al. (2017) · Neuron · doi:10.1016/j.neuron.2017.09.041 · Cited by 48
Specification of Physiologic and Disease States by Distinct Proteins and Protein Conformations
Jarosz, D. F., & Khurana, V. (2017) · Cell · doi:10.1016/j.cell.2017.10.047 · Cited by 46
Soluble tau aggregates inhibit synaptic long-term depression and amyloid β-facilitated LTD in vivo
Ondrejčák, T., Hu, N., Qi, Y., Klyubin, I. V., Corbett, G. T., Fraser, G. M., Perkinton, M. S., Walsh, D. M., Billinton, A., & Rowan, M. J. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2019.03.022 · Cited by 47
Guglietti, B., Sivasankar, S., Mustafa, S., Corrigan, F., & Collins‐Praino, L. E. (2021) · Molecular Neurobiology · doi:10.1007/s12035-021-02518-3 · Cited by 48
The Potential Role of Rho GTPases in Alzheimer's Disease Pathogenesis
Bolognin, S., Lorenzetto, E., Diana, G., & Buffelli, M. (2014) · Molecular Neurobiology · doi:10.1007/s12035-014-8637-5 · Cited by 47
Ayton, S., & Bush, A. I. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2020.101212 · Cited by 45
The secret life of extracellular vesicles in metal homeostasis and neurodegeneration
Bellingham, S. A., Guo, B. B., & Hill, A. F. (2015) · Biology of the Cell · doi:10.1111/boc.201500030 · Cited by 45
Butini, S., Brindisi, M., Brogi, S., Maramai, S., Guarino, E., Panico, A., Saxena, A., Chauhan, V. P. S., Colombo, R., Verga, L., et al. (2013) · ACS Medicinal Chemistry Letters · doi:10.1021/ml4002908 · Cited by 45
The biogenesis and biology of amyloid β oligomers in the brain
Ashe, K. H. (2020) · Alzheimer s & Dementia · doi:10.1002/alz.12084 · Cited by 50
Autophagy-lysosomal pathway impairment and cathepsin dysregulation in Alzheimer’s disease
Mançano, A. S. F., Pina, J. G., Froes, B. R., & Sciani, J. M. (2024) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2024.1490275 · Cited by 51
Béland, M., Bédard, M., Tremblay, G., Lavigne, P., & Roucou, X. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.02.001 · Cited by 44
Regulation of spine structural plasticity by Arc/Arg3.1
Newpher, T. M., Harris, S. C., Pringle, J., Hamilton, C., & Soderling, S. H. (2017) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2017.09.022 · Cited by 45
Recent advancements toward therapeutic vaccines against Alzheimer’s disease
Herline, K., Drummond, E., & Wısnıewskı, T. (2018) · Expert Review of Vaccines · doi:10.1080/14760584.2018.1500905 · Cited by 46
Jarosz-Griffiths, H., Corbett, N. J., Rowland, H. A., Fisher, K., Jones, A. C., Baron, J., Howell, G. J., Cowley, S. A., Chintawar, S., Cader, M. Z., et al. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.005364 · Cited by 45
The 37kDa/67kDa Laminin Receptor acts as a receptor for Aβ42 internalization
Dias, B. D. C., Jovanovic, K., Gonsalves, D., Moodley, K., Reusch, U., Knackmuss, S. H. J., Weinberg, M. S., Little, M., & Weiss, S. F. T. (2014) · Scientific Reports · doi:10.1038/srep05556 · Cited by 44
Assessing the causes and consequences of co-polymerization in amyloid formation
Sarell, C. J., Stockley, P. G., & Radford, S. E. (2013) · Prion · doi:10.4161/pri.26415 · Cited by 44
Transmembrane protein 97 is a potential synaptic amyloid beta receptor in human Alzheimer’s disease
Colom-Cadena, M., Toombs, J., Simzer, E., Holt, K., McGeachan, R., Tulloch, J., Jackson, R. J., Catterson, J. H., Spires-Jones, M. P., Rose, J., et al. (2024) · Acta Neuropathologica · doi:10.1007/s00401-023-02679-6 · Cited by 44
Reelin Signaling in Neurodevelopmental Disorders and Neurodegenerative Diseases
Joly‐Amado, A., Kulkarni, N., & Nash, K. R. (2023) · Brain Sciences · doi:10.3390/brainsci13101479 · Cited by 47
Glimepiride protects neurons against amyloid-β-induced synapse damage
Osborne, C., West, E., Nolan, W., McHale-Owen, H., Williams, A., & Bate, C. (2015) · Neuropharmacology · doi:10.1016/j.neuropharm.2015.09.030 · Cited by 43
Suppression of Alzheimer’s Disease-Related Phenotypes by Geranylgeranylacetone in Mice
Hoshino, T., Suzuki, K., Matsushima, T., Yamakawa, N., Suzuki, T., & Mizushima, T. (2013) · PLoS ONE · doi:10.1371/journal.pone.0076306 · Cited by 45
Botelho, H. M., Leal, S. S., Cardoso, I., Yanamandra, K., Morozova‐Roche, L. A., Fritz, G., & Gomes, C. M. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.396416 · Cited by 46
Sáez-Orellana, F., Fuentes-Fuentes, M. C., Godoy, P. A., Silva-Grecchi, T., Panes-Fernández, J., Guzmán, L., Yévenes, G. E., Gavilán, J., Egan, T. M., Aguayo, L. G., et al. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.10.027 · Cited by 43
Alzheimer’s disease: amyloid-based pathogenesis and potential therapies
Zhou, Y., Sun, Y., Ma, Q., & Liu, Y. (2018) · Cell Stress · doi:10.15698/cst2018.07.143 · Cited by 45
Prion Protein is Reduced in Aging and in Sporadic but not in Familial Alzheimer's Disease
Whitehouse, I. J., Jackson, C. D., Turner, A. J., & Hooper, N. M. (2010) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-101071 · Cited by 43
Onodera, T., Sakudo, A., Tsubone, H., & Itohara, S. (2014) · Microbiology and Immunology · doi:10.1111/1348-0421.12162 · Cited by 43
Presenilin mouse and zebrafish models for dementia: Focus on neurogenesis
van Tijn, P., Kamphuis, W., Marlatt, M. W., Hol, E. M., & Lucassen, P. J. (2010) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2010.10.008 · Cited by 43
Alzheimer’s disease beyond APOE
van Es, M. A., & van den Berg, L. H. (2009) · Nature Genetics · doi:10.1038/ng1009-1047 · Cited by 43
Somatostatin binds to the human amyloid β peptide and favors the formation of distinct oligomers
Wang, H., Muiznieks, L. D., Ghosh, P., Williams, D., Solarski, M., Fang, A., Ruiz‐Riquelme, A., Pomès, R., Watts, J. C., Chakrabartty, A., et al. (2017) · eLife · doi:10.7554/elife.28401 · Cited by 46
Naito, Y., Tanabe, Y., Lee, A. K., Hamel, E., & Takahashi, H. (2017) · Scientific Reports · doi:10.1038/srep42548 · Cited by 42
Zhang, Y.-J., Shi, J., Bai, C., Wang, H., Li, H., Wu, Y., & Ji, S. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.281295 · Cited by 43
Initiation and propagation of neurodegeneration
Haass, C. (2010) · Nature Medicine · doi:10.1038/nm.2223 · Cited by 45
Prion Disease Induces Alzheimer Disease—Like Neuropathologic Changes
Tousseyn, T., Bajsarowicz, K., Sanchez, H. C., Gheyara, A. L., Oehler, A., Geschwind, M., DeArmond, B., & DeArmond, S. J. (2015) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0000000000000228 · Cited by 45
Mechanism of aggregation and membrane interactions of mammalian prion protein
Thody, S. A., Mathew, M. K., & Udgaonkar, J. B. (2018) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2018.02.031 · Cited by 42
Aptamers targeting amyloidogenic proteins and their emerging role in neurodegenerative diseases
Murakami, K., Izuo, N., & Bitan, G. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.101478 · Cited by 43
Wray, S., & Noble, W. J. (2009) · Journal of Neuroscience · doi:10.1523/jneurosci.2234-09.2009 · Cited by 42
Is tau ready for admission to the prion club?
Hall, G. F., & Patuto, B. A. (2012) · Prion · doi:10.4161/pri.19912 · Cited by 43
α-Synuclein and huntingtin exon 1 amyloid fibrils bind laterally to the cellular membrane
Monsellier, É., Bousset, L., & Melki, R. (2016) · Scientific Reports · doi:10.1038/srep19180 · Cited by 43
Sempou, E., Biasini, E., Pinzon‐Olejua, A., Harris, D. A., & Trillo, E. M. (2016) · Molecular Neurodegeneration · doi:10.1186/s13024-016-0076-5 · Cited by 41
Cellular prion protein targets amyloid-β fibril ends via its C-terminal domain to prevent elongation
Bove‐Fenderson, E., Urano, R., Straub, J. E., & Harris, D. A. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.789990 · Cited by 42
High affinity binding of amyloid β -peptide to calmodulin: Structural and functional implications
Corbacho‐Cuello, I., Berrocal, M., Török, K., Mata, A. M., & Gutiérrez‐Merino, C. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.03.151 · Cited by 41
Iron-responsive-like elements and neurodegenerative ferroptosisPreprint
Rogers, J. T., & Cahill, C. M. (2020) · Learning & Memory · doi:10.1101/lm.052282.120 · Cited by 41
Transcriptional and post‐transcriptional regulation of β‐secretase
Tamagno, E., Guglielmotto, M., Monteleone, D., Vercelli, A., & Tabaton, M. (2012) · IUBMB Life · doi:10.1002/iub.1099 · Cited by 40
Gehlot, P., Kumar, S., Vyas, V. K., Choudhary, B. S., Sharma, M., & Malik, R. (2022) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2022.117047 · Cited by 40
Role of calcium dysregulation in Alzheimer's disease and its therapeutic implications
Joshi, M., Joshi, S. S., Khambete, M., & Degani, M. S. (2022) · Chemical Biology & Drug Design · doi:10.1111/cbdd.14175 · Cited by 41
Risse, E., Nicoll, A. J., Taylor, W. A., Wright, D., Badoni, M., Yang, X., Farrow, M. A., & Collinge, J. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.637124 · Cited by 43
Gasperini, L., & Legname, G. (2014) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2014.00044 · Cited by 45
Metadata
- Authors
- Laurén, J., Gimbel, D. A., Nygaard, H. B., Gilbert, J. W., & Strittmatter, S. M.
- Affiliations
- Yale University (US)
- Corresponding author
- Strittmatter, Stephen M.
- Venue
- Nature
- Published
- 2009-02
- Volume
- 457
- Issue
- 7233
- Pages
- 1128-1132
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC2748841
- OpenAlex
- W2171526610
- Cited by
- 1,560
- References
- 37
- Citations by year
- 2026: 46 · 2025: 45 · 2024: 50 · 2023: 52 · 2022: 87 · 2021: 82 · 2020: 85 · 2019: 71 · 2018: 108 · 2017: 117 · 2016: 103 · 2015: 98 · 2014: 104 · 2013: 116 · 2012: 119
- FWCI
- 87.03
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- U.S. Public Health Service (5T32GN07205)
- National Institute on Drug Abuse (P30DA018343)
- National Institute of Neurological Disorders and Stroke (R01NS042304, R01NS039962, R37NS033020)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Prion Diseases and Protein Misfolding
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Keywords
- cellular prion protein, amyloid-beta oligomers, Alzheimer's disease, synaptic plasticity, long-term potentiation, cell surface receptors, lipid rafts, hippocampus, anti-PrP antibodies, prion disease, expression cloning, neurotoxicity, spatial memory, neuroprotection, neurodegeneration
- MeSH terms
- Alzheimer Disease, Amyloidosis, Animals, Chlorocebus aethiops, Hippocampus, Humans, Mice, Inbred C57BL, Neuronal Plasticity, Neurons, Peptide Fragments, Prions, Protein Binding, Receptors, Cell Surface, Synapses, Amyloid beta-Peptides, Long-Term Potentiation, COS Cells, Mice, Amyloid Precursor Protein Secretases, Protein Multimerization
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
